Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

Dmitriy Zamarin; Rikke B. Holmgaard; Jacob Ricca; Tamar Plitt; Peter Palese; Padmanee Sharma; Taha Merghoub; Jedd D. Wolchok; James P. Allison

doi:10.1038/ncomms14340

Nature Communications (Feb 2017)

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

Dmitriy Zamarin,
Rikke B. Holmgaard,
Jacob Ricca,
Tamar Plitt,
Peter Palese,
Padmanee Sharma,
Taha Merghoub,
Jedd D. Wolchok,
James P. Allison

Affiliations

Dmitriy Zamarin: Department of Medicine, Memorial Sloan Kettering Cancer Center
Rikke B. Holmgaard: Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center
Jacob Ricca: Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center
Tamar Plitt: Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center
Peter Palese: Department of Microbiology, Icahn School of Medicine at Mount Sinai
Padmanee Sharma: Department of Immunology, MD Anderson Cancer Center
Taha Merghoub: Weill Cornell Medical College
Jedd D. Wolchok: Department of Medicine, Memorial Sloan Kettering Cancer Center
James P. Allison: Department of Immunology, MD Anderson Cancer Center

DOI: https://doi.org/10.1038/ncomms14340
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 14

Abstract

Read online

Oncolytic viruses induce a variety of immune targets in the infected tumours. Here, the authors show that Newcastle Disease Virus (NDV) upregulates the inducible co-stimulator (ICOS) on T cells and that intratumoral targeting of ICOS with engineered NDV in combination with CTLA-4 blockade induces systemic anti-tumour immunity in mice.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal